In patient #03, for whom a dosimetry comparison between PSMA-TO-1 and PSMA-617 could be completed, the therapeutic index (mean tumor dose/critical organ dose) of 177Lu-PSMA-617/177Lu-PSMA-TO-1 for the kidney, bone marrow and salivary gland was 1.6/0.6, 28.8/18.0 and 0.9/0.8, respectively (Fig. 4). Here, FOLH1 is linked to neoplasm.